Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients

European Journal of Haematology

Volumn 90, Issue 6, 2013, Pages 486-493

  Wu, Lingyun ^a   Li, Xiao ^a   Xu, Feng ^a   Zhang, Zheng ^a   Chang, Chunkang ^a   He, Qi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Apoptosis; Lenalidomide; Myelodysplastic syndrome; Ribosomal protein S14

Indexed keywords

LENALIDOMIDE; RIBOSOME PROTEIN; RPS14 PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; GENE EXPRESSION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; APOPTOSIS; BONE MARROW CELLS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 5; DISEASE-FREE SURVIVAL; ERYTHROBLASTS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RIBOSOMAL PROTEINS; SURVIVAL RATE; THALIDOMIDE;

EID: 84878151899     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12105     Document Type: Article

References (25)

1. Hasserjian RP, Le Beau MM, Bennett JM, List AF, Thiele J. Myelodysplastic syndrome with isolated del(5q). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008: 102-3.
2. Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 1994;84:3253-60.
3. Giagounidis AA, Germing U, Haase S, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004;18:113-9.
4. Pellagatti A, Esoof N, Watkins F, et al. Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. Br J Haematol 2004;125:576-83.
5. Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol 2007;139:578-89.
6. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451:335-9.
7. Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010;16:59-66.
8. Czibere A, Bruns I, Junge B, Singh R, Kobbe G, Haas R, Germing U. Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival. Haematologica 2009;94:1453-5.
9. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361:1872-85.
10. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86:268-76.
11. Li X, Bryant CE, Deeg HJ. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol 2004;80:140-5.
12. Zhou X, Hao Q, Liao J, Zhang Q, Lu H. Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene 2013;32:388-96.
13. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137:413-31.
14. Dutt S, Narla A, Lin K, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2011;117:2567-76.
15. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57.
16. List A, Dewald G, Bennett J, et al. Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65.
17. Fenaux P, Giagounidis A, Selleslag D, et al. MDS-004 Lenalidomide del5q Study Group.A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011;118:3765-76.
18. Oliva EN, Cuzzola M, Nobile F, et al. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. Eur J Haematol 2010;85:231-235.
19. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.
21. Valencia A, Cervera J, Such E, Sanz MA, Sanz GF. Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q- syndrome. Blood 2008;112:918.
22. Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002;99:4638-41.
23. Sohal DS, Pellagatti A, Zhou L, et al. Downregulation of ribosomal proteins is seen in non-5q- MDS. [Abstract]. Blood 2008;112:854. (ASH Annual Meeting Abstracts).
24. Quigley JG, Yang Z, Worthington MT, Phillips JD, Sabo KM, Sabath DE, Berg CL, Sassa S, Wood BL, Abkowitz JL. Identification of a human heme exporter that is essential for erythropoiesis. Cell 2004;118:757-66.
25. Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008;5:e35.